U.S., Nov. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07226947) titled 'Body Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment' on Nov. 06.
Brief Summary: The goal of this study is to learn if a smartwatch that measures activity level and body composition, combined with exercise reminders, can safely improve strength and muscle mass in people who recently started or are planning to start treatment with incretin therapy (liraglutide, semaglutide, tirzepatide or retatrutide), also known as glucagon-like peptide 1 receptor agonist (GLP-1 RA) medications.
Study Start Date: Nov., 2025
Study Type: INTERVENTIONAL
Condition:
Obesity
Body Composition
Intervention:
DEVICE: Smartwat...